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ABSTRACT
MicroRNAs (miRNAs) are a class of endogenous non-coding small RNAs that post-
transcriptionally control the translation and stability of target mRNAs in a sequence-
dependent manner. MiRNAs are essential for key cellular processes including proliferation, 
differentiation, cell death and metabolism, among others. Consequently, alterations of 
miRNA expression contribute to developmental defects and a myriad of diseases. 
The expression of miRNAs can be altered by several mechanisms including gene 
copy number alterations, aberrant DNA methylation, defects of the miRNA processing 
machinery or unscheduled expression of transcription factors. In this work, we sought 
to analyze the regulation of the miR-182 cluster, located at the 7q32 locus, which 
encodes three different miRNAs that are abundantly expressed in human embryonic 
stem cells and de-regulated in cancer. We have found that the Krüppel-like factor 4 
(KLF4) directly regulates miR-182 cluster expression in human embryonic stem cells 
(hESCs) and in melanoma tumors, in which the miR-182 cluster is highly expressed 
and has a pro-metastatic role. Furthermore, higher KLF4 expression was found to be 
associated with metastatic progression and poor patient outcome. Loss of function 
experiments revealed that KLF4 is required for melanoma cell maintenance. These 
findings provide new insights into the regulation of the miR-182 cluster expression and 
new opportunities for therapeutic intervention in tumors in which the KLF4-miR-182 
cluster axis is deregulated.
INTRODUCTION
Non-coding RNAs including microRNAs (miRNAs) 
have emerged as key regulators of development and 
disease [1]. MiRNAs are a class of small non-coding 
RNAs that interfere with the translation and stability of 
coding messenger RNAs (mRNAs) in a sequence-specific 
manner [2]. Mature, biologically-active miRNAs are ~22 
nucleotides in length, and processed from longer primary 
transcripts by the RNAse enzymes Drosha and Dicer in 
the nucleus and cytoplasm, respectively [3]. Despite all 
the knowledge gathered in the last 15 years on their tissue-
specific expression and functional consequences of their 
overexpression or silencing, relatively little is known on their 
own expression regulation. MicroRNA genes are distributed 
along the genome and can be intergenic, intronic (mirtrons), 
or exonic (in exons of coding or non-coding genes). They are 
found as single genes or organized in clusters, i.e, miRNAs 
located in the same genomic region, usually in less than 
10Kb, and transcribed as a single transcriptional unit [4].
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MiRNAs altered in cancer are often located in 
genomic regions that are prone to alterations including 
amplifications or deletions [5]. The high frequency of 
genomic alterations in miRNA loci was confirmed by 
high-resolution array-based genomic hybridization on 
227 human ovarian cancer, breast cancer, and melanoma 
samples [6]. This study proved that miRNA expression 
strongly correlated with gene copy number. Our 
group showed that the melanoma metastasis promoter 
miR-182 is transcribed from the miR-183~96~182 
cluster (hereafter referred as miR-182 cluster) in the 
7q32 chromosomal region. This cluster is frequently 
overexpressed in melanoma tissues and cell lines and 
promotes migration in vitro and metastasis in vivo [7]. In 
around 50% of melanoma cell lines tested (7 out of 14 
cell lines), miR-182 cluster overexpression was linked to 
amplification of the 7q31-34 locus, a region commonly 
amplified in melanoma, but the mechanism(s) underlying 
overexpression in the remaining cases remained unclear. 
This cluster has now been found to be deregulated in other 
tumors and disorders [8] in which genomic amplification 
seems not to be the main cause. Additionally, the miR-182 
cluster is one of the most expressed in human embryonic 
stem cells (hESCs) [9, 10], suggesting a potential role in 
stem cell maintenance and regulation of differentiation. 
In this study, we sought to analyze the transcriptional 
and epigenetic mechanisms that lead to miR-182 cluster 
expression in physiological (i.e. hESCs) and pathological (i.e. 
malignant melanoma) conditions.  We describe the minimal 
promoter region that is sufficient to drive the expression of 
the miR-182 cluster. Among the several transcription factors 
predicted to bind this region, Krüppel-like factor 4 (KLF4) 
showed the highest trans-activation capacity, and expression 
correlation with miR-182 in melanoma cell lines without 
7q amplification. Chromatin Immunoprecipitation (ChIP) 
analysis confirmed the physical binding of KLF4 to the 
miR-182 cluster promoter in melanoma cell lines but not in 
melanocytes, in which miR-182 is not expressed. Moreover, 
KLF4 also occupies the miR-182 cluster promoter in hESCs 
from which is gone during melanocyte differentiation. The 
mechanisms underlying the silencing of the miR-182 cluster 
in the melanocytic lineage involve histone deacetylation 
since the treatment of cells with histone deacetylase 
inhibitors restores miR-182 cluster expression. In sum, our 
study provides new insights into the regulation of this cluster 
in development and cancer and opens up new opportunities 
for therapeutic intervention in tumors in which the KLF4-
miR-182 cluster is deregulated.
RESULTS
KLF4 is sufficient to activate the expression of 
the miR-182 cluster
In an attempt to delineate the functional promoter 
region of the miR-182 cluster, several luciferase reporter 
constructs flanking the predicted transcription start site [10] 
(TSS) (Figure 1A) were generated. Five different fragments 
of the two main CpG islands upstream the TSS were cloned 
upstream the luciferase reporter gene (Figure 1B, left). 
Luciferase activity assays were performed to determine the 
basal trans-activation capacity of those sequences in two 
different cell lines. We found that the ∆1.1 construct, which 
expands 0.9 Kb upstream of the TSS, retains the maximal 
luciferase activity levels across all the constructs tested 
(Figure 1B, right). In silico analysis (MatInspector, [11]) 
revealed that the ∆1.1 region contains 58 putative binding 
sites for 46 different transcription factors (TFs), with one 
or more binding sites conserved between the murine and 
human sequences (Supplementary Table 1).  To narrow 
down the main potential regulator(s) of miR-182 cluster 
expression, we integrated mRNA microarray expression data 
for the 46 TFs with miR-182 levels measured by qPCR in 
a panel of melanoma cell lines without amplification of the 
7q32 locus. Sixteen out of forty-six TFs revealed a positive 
correlation with miR-182 expression levels (Pearson’s value 
> 0.5, Supplementary Table 2, Figure 1C). Eight candidate 
genes (KLF4, KLF10, ZEB1, ZNF83, ZNF148, CEBP, 
BACH1 and PAX9) were selected for further analysis based 
on their higher expression levels in melanoma compared to 
normal melanocytes, and individually tested as potential 
trans-activators of the minimal miR-182 cluster promoter 
in HEK293T cells. KLF4 and PAX9 transient ectopic 
expression significantly enhanced the basal luciferase 
activity of the ∆1.1 reporter construct, indicating that those 
TFs may modulate -directly or indirectly- the activity of 
the miR-182 cluster promoter (Figure 1D, green bars). 
However, in the same experimental samples, miR-182,-96, 
and -183 endogenous levels were only found upregulated in 
KLF4-transduced cells (Figure 1D, orange bars). 
KLF4 binds to the miR-182 cluster promoter 
and is necessary for miR-182 expression
To determine whether KLF4 alone was necessary to 
drive the expression of the miR-182 cluster in melanoma, 
two different shRNAs against KLF4 were transduced 
into melanoma cells resulting in a clear reduction of 
endogenous miR-182 cluster levels (Figure 2A–2B). 
In an attempt to ascertain whether KLF4 directly binds 
to the miR-182 cluster promoter, chromatin immuno-
precipitation (ChIP) experiments were performed. 
Bioinformatic algorithms predict up to ten KLF4 binding 
sites in the promoter of the miR-182 cluster.  Based on our 
luciferase reporter results, four different primer sets were 
designed to cover the KLF4 binding sites with the highest 
(primer sets #2 and #3) or lowest (primer sets #1 and #4) 
binding probability (Figure 2C). ChIP-qPCR experiments 
demonstrated that the RNA polymerase II binds the 
miR-182 cluster promoter in melanoma cells that do 
express the cluster, preferentially around the TSS, but 
not in differentiated cells like the immortal melanocytes 
Oncotarget26300www.impactjournals.com/oncotarget
Figure 1: KLF4 regulates the miR-182 cluster promoter. (A) Representative scheme of the miR-182~96~183 cluster locus. 
(B) Luciferase activity assay using reporter constructs flanking the predicted transcription start site (TSS) of the miR-182 cluster. 
(C) Heat map of the indicated transcription factors showing a positive correlation with miR-182 levels in melanoma cell lines without 7q 
amplification. (D) Luciferase activity assay of the miR-182 cluster promoter (green bars) and correlation with endogenous levels of miR-
182 cluster (orange bars) measured by qPCR. *p < 0.05; **p < 0.01; ***p < 0.001.
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Hermes 2B (Figure 2D). ChIP confirmed KLF4 binding 
to the miR-182 cluster promoter in melanoma cells 
expressing this cluster (i.e. A375 and SK-MEL-147). 
Moreover, we found KLF4 preferentially bound to 
its consensus binding sites located around the TSS 
(Figure 2E). It has been reported that KLF4 needs to 
be acetylated for its trans-activation activity, and that 
acetylation is mediated by the P300/CBP complex [12]. 
Indeed, we found P300 co-localizing with KLF4 in the 
miR-182 cluster promoter region (Figure 2F). In summary, 
these results demonstrate that KLF4 binds to the miR-182 
cluster promoter and is necessary to drive miR-182 cluster 
expression in melanoma cells.
KLF4 is a physiological regulator of the miR-182 
cluster
KLF4 is a key regulator of pluripotency and self-
renewal capacity of human embryonic stem cells (hESCs) 
[13]. Since the miR-182 cluster has been shown to be 
abundantly expressed in mouse and hESCs [10], we 
investigated whether KLF4 could also be responsible 
for this miRNA cluster expression in that physiological 
context. We found that miR-182 cluster is highly 
expressed in hESCs and progressively repressed during 
differentiation towards melanocytes, paralleling the 
increase in melanocyte differentiation markers, such 
as MITF-M (Figure 3A). We confirmed that miR-182 
suppression was not just a general consequence of a 
defect in the miRNA processing machinery, as levels of 
DICER1, DROSHA and DGCR8 showed no correlation 
with the miR-182 cluster levels during the hESCs to 
melanocyte differentiation time-course (Supplementary 
Figure 1). However, a direct association between miR-182 
and KLF4 levels was observed during the differentiation 
time course. As a control, other KLF family members, 
KLF2 and KLF5, were found stably expressed over the 
differentiation period (Figure 3B). Again, ChIP analysis 
showed KLF4 occupancy of the miRNA cluster promoter 
in hESCs cells and progressive loss of binding during 
melanocytic differentiation (Figure 3C). A parallel pattern 
was observed for P300 (Figure 3D). Concurring with our 
results, data mining of ChIPseq analysis of mouse ES 
cells revealed KLF4 occupancy of the miR-182 cluster 
promoter (Supplementary Table 3) [14].
miR-182 is induced by HDAC inhibitor but not 
by DNA methyl-transferase inhibitor treatment
To expand our characterization of the miR-182 
cluster’s regulation in the melanocytic lineage, we 
examined whether epigenetic mechanisms could be 
responsible for the regulation of the miR-182 cluster 
in differentiated hESCs and melanoma cells in which 
this cluster is very lowly expressed or undetectable. 
Treatment with the DNA methyltransferase inhibitor 
5′-azacytidine was unable to induce miR-182 levels 
on immortal melanocytes or melanoma cells lacking 
miR-182 expression (Figure 4A), suggesting that 
promoter DNA methylation does not account for this 
cluster silencing during differentiation or in those cells. 
However, treatment of immortal melanocytes with the 
HDAC inhibitor Trichostatin A (TSA) resulted in miR-182 
upregulation in a time (Figure 4B) and dose-dependent 
manner (Figure 4C). The same effect was also observed 
in melanoma cell lines harboring low miR-182 levels 
(Figure 4D). Of note, increased histone acetylation levels 
were found in the cluster promoter on melanoma cell lines 
that express the cluster compared to immortal melanocytes 
(Figure 4E). Moreover, histone acetylation at the promoter 
also decreases during hES cells differentiation to 
melanocytes (Figure 4F).
Interestingly, it has been reported that KLF4 
levels are regulated by histone deacetylase inhibitors 
(HDACi) in colon cancer cell lines [15] so we tested if 
in melanoma cells, HDACi treatment was able to induce 
KLF4 expression. Treatment of melanocytes with TSA 
resulted in KLF4 upregulation paralleling miR-182 cluster 
induction (Figure 4G). The same effect was observed in 4 
out of 5 melanoma cell lines (Figure 4H).
Overall, our results support a two-step model 
of miR-182 cluster regulation consisting of histone 
acetylation relaxing the chromatin structure and thus 
permitting physical access of TFs, such as KLF4, to the 
promoter region. During normal differentiation, loss of 
histone acetylation and KLF4 expression (among other 
regulatory TFs) might lead to silencing of the cluster. 
Aberrant expression of the miR-182 cluster in melanoma 
cells may be due to enhanced histone acetylation of the 
promoter region together with altered expression of 
necessary TFs (see Figure 6D). 
KLF4 is essential for melanoma migration, 
invasion and growth
Several reports support a pro-metastatic role of 
the miR-182 cluster by promoting migration, invasion 
and survival of tumor cells in a number of malignancies 
including melanoma [7]. Therefore, we sought to analyze 
whether KLF4 could be regulating similar processes and 
potentially be a new therapeutic target in melanoma. In 
fact, gene expression analyses in metastatic melanoma 
samples (GSE19324, n = 44) showed higher levels of 
KLF4 mRNA in patients with poor outcome (Figure 5A) 
suggesting that KLF4 could contribute to melanoma 
metastatic progression. Concurring with this hypothesis, 
shRNA mediated knockdown of KLF4 in melanoma cells 
(Figure 5B) reduced their ability to migrate in a wound-
healing assay (Figure 5C–5D) and to invade in a transwell 
cell invasion assay (Figure 5E). Furthermore, a drastic 
reduction in cell viability and colony formation capacity 
was observed upon shRNA-mediated silencing of KLF4 
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Figure 2: KLF4 controls miR-182 expression in melanoma cells. (A) Western blot showing KLF4 knockdown 72 hours post-
infection with the indicated shRNA lentiviral particles. (B) Expression levels of miR-182 cluster members upon KLF4 silencing in the 
indicated melanoma cell lines, measured by qPCR. (C), Representative scheme of the miR-182 cluster locus with KLF4 putative binding 
sites (in blue), and primer sets used in ChIP (black). (D–F), ChIP assay of RNA Pol II (D), KLF4 (E) and EP300 (F). *p < 0.05; **p < 0.01; 
***p < 0.001.
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at longer time points (Figure 6A–6C). These data suggest 
that KLF4 confers increased survival and aggressiveness 
to melanoma cells. However, the overexpression of 
miR-182 was not able to rescue the effects of KLF4 
silencing (data not shown), thereby suggesting that other 
KLF4 targets may also be relevant to KLF4 pro-survival 
effects in melanoma. 
DISCUSSION
The regulation of miRNA expression is complex 
and remains undetermined for most miRNAs. In the 
present study, we focus on the regulation of the miR-
182 cluster expression, shown to be deregulated in 
multiples pathologies [8] and functionally contributing to 
development of sensory organs and progression of different 
tumor types such as melanoma (reviewed in [16]).
The miR-182 cluster gene is a large intergenic 
miRNA gene located in the reverse strand of the long 
arm of the human chromosome 7 (7q32.2). The primary 
transcript encodes three different miRNAs (i.e. miR-183, 
miR-96 and miR-182) which are highly homologous in 
their seed sequence, especially in the case of miR-96 
and miR-182, thereby suggesting a significant number of 
potentially shared targets. 
The first suggestion of a physiological role of this 
cluster was reported by Xu and colleagues who found 
miR-182 cluster levels upregulated during the retina 
development [17]. Moreover, loss of function experiments 
in zebrafish demonstrated that the miR-182 cluster is 
necessary for the proper development of sensory epithelia 
in the inner ear [18].
In addition to its physiological role, aberrant 
expression of the miR-182 cluster or its components has 
been reported in several diseases including auto-immune 
disorders, neuronal and psychiatric disorders and in multiple 
tumor types (reviewed in [8]). In cancer, most of the 
reports showed a pro-oncogenic role (e.g. prostate cancer 
[19], melanoma [7], ovarian cancer [20]) although tumor 
suppressor roles have also been proposed (e.g. osteosarcoma 
[21]), suggesting context-dependent functions.
Despite being a highly relevant cluster, very little 
information exists on the regulation of its expression 
under physiological and pathological conditions. 
Chiang et al. found β-catenin/TCF4 binding sites in the 
promoter of miR-182 cluster and showed that the genetic 
Figure 3: KLF4 regulates the miR-182 cluster expression in hES cells. (A–B) Expression levels of the indicated genes during 
a hESCs to melanocyte differentiation time course measured by qPCR (n = 3/ condition). (C–D) ChIP assay of KLF4 and EP300 during 
hESCs to melanocyte differentiation protocol (n = 3/ condition). * or #p < 0.05; ** or ##p < 0.01; *** or ###p < 0.001.
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Figure 4: miR-182 is re-expressed upon histone deacetylase inhibition. (A) MiR-182 expression levels measured by qPCR in 
immortal melanocytes (grey bars) and melanoma cells (black bars) treated with the DNA methyltransferase inhibitor 5′-azacytidine for the 
indicated times. The histone deacetylase inhibitor Trichostatin A (TSA) was added for 24 h only at the 96 h time-point of 5-aza treatment. 
(B) Immortal melanocytes treated with 200 ng/ml of TSA for the indicated times. MiR-182 levels were measured by qPCR. (C) MiR-182 
expression in immortal melanocytes treated with the indicated amounts of TSA during 24 h. (D) MiR-182 levels were measured by qPCR in 
the indicated melanoma cell lines treated with 200 ng/ml of TSA for 24 h. (E) ChIP assay of activating histone acetylation marks (H3K18Ac) 
at the miR-182 cluster promoter in melanoma cell lines and in immortal melanocytes, and (F) during hESC to melanocyte differentiation 
time course. (G) KLF4 levels measured in immortal melanocytes treated with the indicated doses of TSA for 24 h. (H) Normal immortal 
melanocytes (Hermes) and melanoma cell lines treated with 200 ng/ml of TSA for 24 h. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 5: KLF4 silencing impairs migration and invasion. (A) KLF4 mRNA expression in metastatic melanoma samples 
(GSE19324, n = 44). (B) Western blot showing shRNA-mediated KLF4 efficiency in the indicated transduced melanoma cell lines. 
(C) Wound-healing assay on A375 or SK-MEL-147 (D) stably transduced with either non-silencing control (NSC) or two different shRNA 
against KLF4 (R1,R2). Pictures were taken at the indicated times. Graph represents the area of the remaining open wound calculated in 
relation to time 0 separation (n = 6). (E) Transwell cell invasion assay in melanoma cells infected with control (NSC) and shKLF4 (R1 and 
R2) lentiviral particles. Invaded cells were stained with crystal violet (n = 3). *p < 0.05; **p < 0.01; *** or $$$p < 0.01.
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Figure 6: KLF4 silencing reduces cell viability. (A–B) Cell Viability assay in melanoma cells infected with control (NSC) and 
shKLF4 (R1 and R2) lentiviral particles. Number of viable cells was scored with an automatic cell counter every 48 h (n = 3). (C) Colony 
formation assay in shNSC, shKLF4 R1 and shKLF4 R2 infected melanoma cells (n = 3). (D) Schematic representation of the KLF4-
miR-182 cluster regulation under physiological and pathological situations. ** or $$p < 0.01; *** or $$$p < 0.01.
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or pharmacological inhibition of β-catenin impacted 
negatively on miR-182 levels in breast cancer cell lines 
[22]. Concurring with their results, the WNT/β-catenin 
pathway was also shown to be relevant for miR-182 
cluster expression in gastric [23] and hepatocellular 
carcinomas [24]. In melanoma, the WNT pathway may 
elicit different responses depending on whether the 
canonical or non-canonical pathway is activated. Recent 
evidence support that the canonical WNT pathway may 
be involved in the transformation and proliferation of 
melanoma cells whereas the switch to the non-canonical 
WNT pathway may be more relevant to invasion and 
metastasis [25]. Our in silico analysis revealed several 
WNT-related TF binding sites (i.e. TCF/LEF) but these 
TFs were not further investigated owing to the lack of 
correlation with miR-182 levels in melanoma cell lines 
without 7q genomic locus amplification. We cannot 
rule out the possibility that the WNT pathway may also 
contribute to miR-182 cluster expression in melanomas 
with different genetic background or molecular contexts. 
Another set of reports propose that the growth factor 
TGF-β regulates the expression of the miR-182 cluster 
in glioma [26], gallbladder cancer metastasis [27], 
prostate cancer bone metastasis [28] and breast cancer 
[29] but the specific mediators of TGFβ effects were not 
identified. In melanoma, TGF-β has also been shown to 
exert tumor promoting functions boosting cell motility 
and invasiveness [30]. Our promoter analysis revealed two 
bindings sites (1 also conserved in mouse) for SMAD3, 
a well-characterized effector of the TGF-β pathway. 
However, siRNA-mediated knockdown of SMAD3 did 
not produce alterations in miR-182 levels in melanoma 
cell lines (Supplementary Figure 2). 
Recently, the Kruppel like factor-3 (KLF3) has been 
shown to repress the expression of miR-182 in soft tissue 
sarcomas (STS) [31] where miR-182 has a pro-metastatic 
role [32]. Sachdeva et al. focused on KLF3, KLF11 and 
KLF15 since are the KLF factors with higher expression 
in skeletal muscle. Concurring with their results, we also 
did find several KLF binding sites in the miR-182 cluster 
promoter. Among them, KLF4 and KLF10 where those 
TFs that best correlate with miR-182 in melanoma cell 
lines. However, our experimental validation determined 
that only KLF4 is bound to the promoter region of the 
miR-182 cluster in physiologic conditions (hESCs) and in 
a subset of melanoma cell lines.
In the cancer context, KLF4 has mostly been 
described as a tumor suppressor. However, there is 
growing evidence that KLF4 may also behave as an 
oncogene or a pro-metastatic factor, properties frequently 
attributed to the miR-182 cluster. For example, KLF4 
expression and nuclear localization has been found 
associated with an aggressive phenotype in early breast 
cancer [33] and part of a stem cell-like signature in poorly 
differentiated aggressive human tumors [34]. Furthermore, 
KLF4 mediates resistance to therapy (i.e. lapatinib) [35] 
and  is required for the maintenance of breast cancer stem 
cells and for migration and invasion [36]. In prostate 
cancer, where the miR-182 cluster also is highly expressed 
[37], indicative of poor prognosis [38] and drives 
proliferation and invasion [39], KLF4 has been reported 
to contribute to the progression and have a key role on 
migration and proliferation of prostate cancer cells in vitro 
and in vivo [40]. With all these evidence, it is tempting to 
speculate that some of the pro-metastatic roles of KLF4 
might be attributed to the miR-182 cluster. 
In addition to changing tumor cell intrinsic 
properties, the KLF4-miR-182 cluster axis could 
contribute to tumor progression by altering the metastatic 
niche. All members of the miR-182 cluster have been 
found in exosomes fractions (Exocarta, [41]) and thus 
may be transferred from stromal tissue to tumor cells as 
it have been described for other pro-oncogenic miRNAs 
[42]. Interestingly, high KLF4 levels in normal tissues 
surrounding colorectal tumors were found indicative 
of poor prognosis [43] suggesting that some KLF4 
downstream effectors, such as the miR-182 cluster, 
maybe transferred from normal to tumor cells, thereby 
contributing to tumor genesis or progression. 
As most TFs, KLF factors have been considered 
traditionally ‘undruggable’, but a new class of small 
molecules able to block the interaction between KLF10 
and DNA has been recently developed [44]. These 
compounds bind to the DNA binding zing-finger domain, 
a structure common to all KLF members. Therefore, 
the development of new compounds against other 
KLF members is now foreseen as feasible. Besides the 
direct pharmacologic approach, KLF4 activity maybe 
modulated indirectly. On the one hand, KLF4 needs to 
be acetylated for its trans-activation activity [14] thus 
treatment with small molecule inhibitors of histone 
acetyl-transferases (e.g. P300, CBP) should result in 
reduced levels of KLF4 targets. In this regard, P300 
inhibition in primary melanoma cells suppressed cell 
proliferation and enhanced cell death when combined 
with chemotherapeutic agents such as cisplatin [45]. On 
the other hand, KLF4 expression levels can be modulated 
with targeted short interference RNAs (siRNAs) or 
miRNAs. In fact, KLF4 is a reported target of miR-10b in 
several contexts such as esophageal cancer [46], bladder 
cancer [47] or gastric carcinoma [48]. Interestingly, miR-
10b was reported to be one of the most downregulated 
miRNAs in melanoma [49], suggesting that miR-10b 
restoration could have a therapeutic impact in melanoma 
through the downregulation of KLF4.
In summary, our findings reveal KLF4 as a key 
regulator of miR-182 cluster expression in hESCs and a 
main contributor to its aberrant expression in melanoma 
and potentially in other tumors, thereby providing 
potential new avenues for therapeutic intervention. 
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MATERIALS AND METHODS
Cell lines and reagents
SK-MEL-19, -94, -103, -147, -187 and -192 
melanoma cell lines were kindly provided by Alan 
Houghton (Memorial Sloan–Kettering Cancer Center) 
and Hermes cells by Dorothy Bennett (University College 
London); 501mel were obtained from Yale University. 
HEK293T and A375 cells were acquired from the 
American Type Culture Collection. The B16F10 Human 
melanocytes were purchased from Lonza (adult and 
neonatal) and Yale University. Melanocytes, Hermes, and 
SK-MEL and WM cell lines were cultured as described 
[50]. Human embryonic stem cells were obtained from 
WiCell and maintained in co-culture with MITC-treated 
MEFs in the presence of FGF (10 ng/ml; R&D) under 
conditions described by the supplier. All cultures were 
maintained at 37ºC in a saturated atmosphere of 95% 
air and 5% CO2. 5-aza-2ʹ-deoxycytidine (5-aza) and 
trichostatin A (TSA) were purchased from Sigma.
Plasmids
The pCMV-SPORT6-KLF10 and pCMV-SPORT6-
KLF4 constructs were purchased from Open Biosystems. 
The vectors pCMV6-XL4-BACH1, pCMV6-XL5-PAX9, 
pCMV6-XL5-ZNF148, pCMV6-XL5-ZNF83, pCMV6-
AC-CEBPB, and pCMV6-XL-ZEB1 were purchased 
from Origene (Rockville, MD, USA). For transactivation 
experiments, transfection efficiency (70–75%) was monitored 
by scoring GFP positive cells at 48 hours post-transfection.
For miR-182 cluster promoter analysis, the different 
indicated constructs were generated by PCR amplification 
from genomic DNA and cloned into the pGL4-luciferase 
reporter vector (Promega).
Microarray expression analysis
The expression levels of the TFs of interest were 
analyzed from a gene expression dataset of 20 melanoma 
cell lines previously published by our group (GSE22301), 
[51]. Array expression values were median centered and 
log2 transformed. Heatmaps were generated using the 
MultiExperiment Viewer software (Boston, MA, USA). 
Gene expression data of melanoma patients (GSE19324, 
n = 44) was used to analyze KLF4 expression in metastatic 
melanoma samples.
Luciferase assay 
HEK293T or A375 melanoma cell lines were seeded 
into 96-well plates and co-transfected with 100 ng of the 
indicated promoter luciferase reporter constructs and 
100 ng of the indicated TFs or empty vector (pCDNA3). 
Luciferase activity was measured using the Dual-Glo 
Luciferase Assay System (Promega). Renilla luciferase 
activity was normalized to corresponding firefly luciferase 
activity and plotted as a percentage of the control.
Lentiviral production and KLF4 knockdown
pLKO-NSC, pLKO-shKLF4-R1 and pLKO-
shKLF4-R2 were purchased from Sigma-Aldrich (Madrid, 
Spain). Lentiviruses were propagated using previously 
described methods [52]. Melanoma cells were transduced 
with viral supernatant and selected with 2 µg/ml Puromycin 
for 48 h. KLF4 knockdown efficiency was monitored by 
western blot.
Real-Time quantitative PCR
Total RNA was extracted using the miRNAeasy 
Mini Kit (Qiagen). For microRNA expression analysis, 
quantitative real-time PCR (qRT-PCR) analysis of mir-
182, -96, -183, was performed by using miRNA-specific 
TaqMan MicroRNA Assay Kit (Applied Biosystems); 
Briefly, 12.5 ng of total RNA were reversed transcribed 
using the corresponding RT Primer and the TaqMan 
MicroRNA Reverse Transcription Kit (Applied 
Biosystems). PCR was performed on 1.33 µl of RT 
products by adding the TaqMan PCR primers and the 
TaqMan Universal PCR Master Mix (Applied Biosystems). 
U6 and RNU44 small RNAs were used for normalization. 
For mRNA analysis, 1 μg of total RNA was then subjected 
to DNase treatment and retrotranscription using the 
High-Capacity cDNA reverse transcription kit (Applied 
Biosystems, Alcobendas, Spain). Real-time PCR of KLF2, 
KLF4, KLF5 and MITF genes was performed using SYBR 
green fluorescence (Applied Biosystems). GAPDH was 
used as an internal standard. Primers sequences are listed 
in Supplementary Table 4. Relative quantification of gene 
expression was performed with the 2(−ΔΔCt) method [53].
Western blot
Cell lysates were obtained in RIPA buffer (Pierce, 
Thermo Scientific), supplemented with 1x EDTA-free 
complete protease inhibitor cocktail (Roche). Protein 
concentration was quantified by a modified Lowry assay 
(DC protein assay; Bio-Rad). 30 µg of protein were 
resolved in NuPAGE 4–12% Bis-Tris gels and transferred 
to iBlot® Gel Transfer Stacks PVDF membranes (Life 
Technologies, Thermo Fisher Scientific). After blocking 
with Tris-buffered saline with Tween-20 containing 5% 
non-fat dry milk or 5% BSA for 1 h at room temperature, 
membranes were probed overnight at 4°C with the 
following antibodies: anti-KLF4 [1:1000, Santa Cruz #sc-
20691]; anti-Rabbit IgG-Peroxidase antibody produced in 
goat [1:10.000, Sigma-Aldrich #A0545] and anti-Actin 
HRP [1:40.000, Santa Cruz #sc-1616]. Membranes were 
developed with SuperSignal Dura detection kit (Pierce) 
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or EZ-ECL Chemiluminiscence detection kit (Biological 
Industries, Kibbutz Beit-Haemek, Israel).
Chromatin immunoprecipitation
Chromatin Immunoprecipitation experiments were 
performed using the EZ-Magna ChIP™ A (Millipore) 
following manufacturer’s instructions. Briefly, 1 × 107 
cells were fixed with 1% formaldehyde and nuclei were 
isolated and sonicated to generate ~500-1000 bp DNA 
fragments. Fragmented chromatin was incubated with 1 µg 
of RNA pol II, EP300, Histone 3, H3K18Ac, KLF4 or IgG 
control antibodies (Abcam) and immunoprecipitated with 
protein A magnetic beads. After washes, protein/DNA 
immunoprecipitates were eluted and reverse crosslinked 
with Proteinase K at 62° for 2 h. ChIP and input DNA 
were quantified by RT-qPCR. Expression values were 
normalized versus total Histone 3 signal.
hESC differentiation
H9-hES cells were induced to form Embryo Bodies 
for 4 days followed by a transfer to differentiation 
media (0.02 μm Dexamethasone, 1X Insulin-transferrin-
selenium, 1 mg/ml linoleic acid-bovine serum albumin, 
30% Low Glucose DMEM, 20% MCDB 201, 0.1 mM 
L-ascorbic-acid, 50% Wnt3-Conditioned media, 50 ng/ml 
hSCF, 100 nM EDN3, 20pM cholera toxin, 50 nM TPA, 
4 ng/ml bFGF) and seeded in 6 replicates. Media was 
changed daily and cells were collected after 0, 3, 9, 15 and 
21 days of differentiation.
Wound-healing migration assay
An artificial “wound” was created on a confluent 
cell monolayer (2 × 106 cells in 6-well plates) of A375 
and SK-MEL-147 melanoma cells previously transduced 
with pLKO-NSC or shKLF4-R1 and R2 lentiviral vectors. 
Six preset fields per condition were photographed at the 
indicated times. The migration capability of melanoma cells 
was calculated as a percentage of wound healing vs. time 
0. The wound area was calculated using Image J software 
(National Institutes of Health, Bethesda, MD, USA).
Transwell cell-invasion assay
A suspension of 2 × 105 A375 and 1.5 × 105 SK-
MEL-147 melanoma cells previously transduced with 
shRNAs (NSC, R1 and R2) was added in serum-free 
media to matrigel-coated (0.87 mg/ml) 8-µm-pore 
cell culture inserts (Falcon Discovery Labware; BD 
Biosciences). Cells were incubated for 24 h under 
standard culture conditions and complete media in the 
lower part of the chamber. Viable cells that had migrated 
to the lower transwell chamber were stained with crystal 
violet. Crystals were dissolved in 15% acetic acid and the 
absorbance was measured at 590 nm.
Cell viability and colony formation
For cell viability assays, pLKO-NSC or shKLF4-R1 
and R2 transduced melanoma cells were seeded at 200,000 
cells into 35 mm-dish with counted and reseeded at days 
2, 4 and 6 (n = 3/condition). For colony formation assays, 
pLKO-NSC or shKLF4-R1 and R2 infected melanoma 
cells were seeded at 2,500 cells/well in 6-well plates in 
triplicates with 0.5 µg/mL of puromycin. Medium was 
refreshed every 3 days and cells were allowed to grow 
for 10–15 days. Then, cells were stained with crystal 
violet. Crystals were dissolved in 15% acetic acid and the 
absorbance was measured at 590 nm.
Statistical methodologies
Statistical significance was determined by unpaired 
t-test (GraphPad Prism Software) and McNemar’s test for 
correlations of expression data.
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